Doç. Dr. Kadriye Bir Yücel

Doctor and researcher Ankara Etlik Şehir Hastanesi Ankara
Breast NeoplasmsStomach NeoplasmsCarcinoma, Renal CellKidney NeoplasmsRectal NeoplasmsNeoplasmsGastrointestinal Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 5 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Stomach Neoplasms 4 publications
  • Carcinoma, Renal Cell 3 publications
  • Kidney Neoplasms 3 publications
  • Rectal Neoplasms 2 publications
  • Neoplasms 2 publications
  • Gastrointestinal Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • Department name at the sourceOnkolojisaglik.gov.trFrom source
  • InstitutionAnkara Etlik Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 5 publications · Model version —From source
  • Publications67 publicationsOpenAlex, ORCID, Europe PMCFrom source
  • ORCID0000-0002-4745-1605ORCIDFrom source
  • Last synchronised5 November 2026 07:23https://etliksehir.saglik.gov.tr/TR-864408/klinik-doktorlarimiz.html#kadriye-bir-yucelsaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

67 publications

  1. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041657 PMID 41753346 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104936 PMID 42777557 Open-access full textSource: ORCID

  3. Claudin 18.2 Positivity Thresholds and Candidate Populations for Targeted Therapy in Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Cohort

    Cancers, 2026

    DOI 10.3390/cancers18172827 PMID 42738347 Open-access full textSource: OpenAlex

  4. Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation

    The oncologist, 2026

    DOI 10.1093/oncolo/oyag396 PMID 42836684 Open-access full textSource: Europe PMC

  5. Structural Acceleration in Sepsis-Associated Cancer Mortality in an Aging Population: A Nationwide Study in the United States, 1999–2020

    SSRN Electronic Journal, 2026

    DOI 10.2139/ssrn.6201853 Open-access full textSource: OpenAlex

  6. Temporal Trends and Demographic Disparities in Prostate Cancer Mortality in the United States, 1999-2020: A CDC WONDER Analysis

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-8-1 Open-access full textSource: OpenAlex

  7. Predicting Pathologic Response in Locally Advanced Rectal Cancer Using Inflammatory, Nutritional, and Sarcopenia-Based Markers: A Regression and AI-Based Analysis (CINR-AI Study)

    Clinical Colorectal Cancer, 2026

    DOI 10.1016/j.clcc.2025.10.002 PMID 41198426 1 citation (Europe PMC) Source: ORCID

  8. Quality of Life and Patient-Reported Outcomes During First-Line Chemotherapy in Older Patients with De Novo Metastatic Gastrointestinal Cancers: A Prospective Longitudinal Study

    Healthcare, 2026

    DOI 10.3390/healthcare14203458 PMID 42940505 Open-access full textSource: ORCID

  9. C-Reactive Protein–Albumin–Lymphocyte Index and the Modified Glasgow Prognostic Score as Predictors of Early Mortality After Palliative Percutaneous Transhepatic Biliary Drainage in Malignant Biliary Obstruction

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15124608 PMID 42355776 Open-access full textSource: ORCID

  10. Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer

    Supportive Care in Cancer, 2026

    DOI 10.1007/s00520-026-11216-6 PMID 42726154 Source: OpenAlex

View all 67 publications